Sintilimab Injection

DRUG15 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, The First Hospital of Jilin University, Sichuan Cancer Hospital and Research Institute, The Second Hospital of Shandong University, Zhejiang University

Conditions

Advanced / Metastatic Solid TumorAdvanced Intrahepatic CholangiocarcinomaAdvanced Solid TumoursFirst-line TreatmentGastric CancerHepatocellular CarcinomaIIIA Stage Non-small Cell Lung CancerImmune Related Adverse Events

Phase 1

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Tianjin Medical University Cancer Institute and HospitalFirst-line Treatment, Non-small Cell Lung Cancer

Start: 2019-06-01End: 2021-06-01Target: 30Updated: 2020-07-07

Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment

The Second Hospital of Shandong UniversityGastric Cancer

Start: 2020-09-30End: 2022-06-30Target: 45Updated: 2020-09-28

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

RecruitingNCT05804526

RemeGen Co., Ltd.Advanced Solid Tumours

Start: 2023-07-19End: 2025-12-31Target: 82Updated: 2024-04-30

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

RecruitingNCT06530251

AkesoHepatocellular Carcinoma

Start: 2024-09-24End: 2028-09-01Target: 280Updated: 2026-03-04

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

Not yet recruitingNCT06888648

Zhejiang UniversityPancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable

Start: 2025-04-01End: 2028-04-01Target: 30Updated: 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Not yet recruitingNCT06888674

Zhejiang UniversityPancreatic Cancer Resectable

Start: 2025-04-01End: 2029-04-01Target: 60Updated: 2025-03-21

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

RecruitingNCT06956716

Zhejiang UniversityAdvanced Intrahepatic Cholangiocarcinoma

Start: 2025-04-09End: 2028-04-01Target: 30Updated: 2025-05-04

Study of ABO2102 in KRAS-Mutated Solid Tumors

Not yet recruitingNCT07455617

Suzhou Abogen Biosciences Co., Ltd.Advanced / Metastatic Solid Tumor

Start: 2026-02-01End: 2030-02-01Target: 101Updated: 2026-03-06

Phase 2

Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer

Active, not recruitingNCT04326153

The First Hospital of Jilin UniversityIIIA Stage Non-small Cell Lung Cancer

Start: 2020-03-20End: 2027-12-31Updated: 2024-02-01

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Sichuan Cancer Hospital and Research InstituteLung Diseases, Neoplasms, Non-small-cell Lung Cancer +2

Start: 2020-05-10End: 2021-12-30Target: 20Updated: 2020-05-01

Perioperative Therapy for Hepatocellular Carcinoma

TerminatedNCT04653389

Zhejiang UniversityHepatocellular Carcinoma

Start: 2020-12-26End: 2021-12-01Updated: 2022-01-11

Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer

Active, not recruitingNCT04836728

Tianjin Medical University Cancer Institute and HospitalFirst-line Treatment, Non-small Cell Lung Cancer Metastatic

Start: 2021-03-31End: 2026-12-31Target: 156Updated: 2025-03-13

Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

Not yet recruitingNCT06523049

Hao ZengImmunotherapy, Molecular Targeted Therapy, Renal Cell Carcinoma

Start: 2024-08-31End: 2026-09-30Target: 67Updated: 2024-07-26

Unknown Phase

Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

RecruitingNCT04840355

Guohui LiImmune Related Adverse Events, PD-1

Start: 2021-02-26End: 2025-11-14Target: 100Updated: 2024-12-27

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

RecruitingNCT06353646

Wu WenmingPancreatic Cancer

Start: 2024-03-12End: 2026-12-01Target: 28Updated: 2026-02-13

Related Papers

Circulating CD28-KLRG1+CD8+ T cells as prognostic indicators in advanced NSCLC chemoimmunotherapy.

Journal of Clinical Oncology2025-05-28

Abstract 2862: Anti MSLN ADC RC88 engages unique binding to target positive tumor cells with less interference from the soluble MSLN protein

Cancer Research2025-04-21

VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy.

Journal of Clinical Oncology2025-02-10

Tumor microenvironment(TME) and single-source dual-energy CT(ssDECT) on assessment of inconformity between RECIST1.1 and pathological remission in neoadjuvant immunotherapy of NSCLC

Neoplasia2024-02-132 citations

Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.

2024-01-1917 citations

Long-term outcome for patients with advanced non‒small-cell lung cancer treated by autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy: NSCLC-CCICC-002.

Journal of Clinical Oncology2023-06-011 citations

A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer

Clinical Lung Cancer2022-07-2135 citations

CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer

Cell Death and Disease2022-05-0642 citations

Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.

2022-02-2231 citations

A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)-CCICC-002.

Journal of Clinical Oncology2021-05-202 citations

[Application of Neoadjuvant Immuno-chemotherapy in NSCLC].

2021-04-015 citations